Literature DB >> 28805111

Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.

Aman Sharma1.   

Abstract

Drug resistance in cancer cells remains a fundamental challenge. Be it nontargeted or targeted drugs, the presence of intrinsic or acquired cancer cell resistance remains a great obstacle in chemotherapy. Conventionally, a spectrum of cellular mechanisms defines drug resistance including overexpression of antiapoptotic proteins and drug efflux pumps, mutations in target and synergistic activation of prosurvival pathways in tumor cells. In addition to these well-studied routes, exosome-induced chemoresistance is emerging as a novel mechanism. Mechanistically, exosomes impart resistance by direct drug export, transport of drug efflux pumps and miRNAs exchange among cells. Moreover, exosome signaling creates 'therapeutic tumor heterogeneity' and favorably condition tumor microenvironment. Here, we discuss exosomes' role in chemoresistance and possibilities of developing novel therapeutic strategies.

Entities:  

Keywords:  P-gp; cancer; chemoresistance; drug; exosome; fibroblast; heterogeneity; miRNAs; resistance cell clones; stroma

Mesh:

Substances:

Year:  2017        PMID: 28805111     DOI: 10.2217/nnm-2017-0184

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  22 in total

Review 1.  Ceramide and Exosomes: A Novel Target in Cancer Biology and Therapy.

Authors:  Ahmed Elsherbini; Erhard Bieberich
Journal:  Adv Cancer Res       Date:  2018-06-09       Impact factor: 6.242

2.  Role of HSP27 in the multidrug sensitivity and resistance of colon cancer cells.

Authors:  Zhengyong Liu; Yi Liu; Yupeng Long; Baohua Liu; Xiangfeng Wang
Journal:  Oncol Lett       Date:  2020-01-07       Impact factor: 2.967

Review 3.  Exosome-like Nanovectors for Drug Delivery in Cancer.

Authors:  Noemi Arrighetti; Claudia Corbo; Michael Evangelopoulos; Anna Pastò; Valentina Zuco; Ennio Tasciotti
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

4.  The Role and Underlying Mechanism of Exosomal CA1 in Chemotherapy Resistance in Diffuse Large B Cell Lymphoma.

Authors:  Yuhua Feng; Meizuo Zhong; Youhong Tang; Xianling Liu; Yiping Liu; Leyuan Wang; Hui Zhou
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-24       Impact factor: 8.886

Review 5.  Therapy resistance mediated by exosomes.

Authors:  Teresa Bernadette Steinbichler; József Dudás; Sergej Skvortsov; Ute Ganswindt; Herbert Riechelmann; Ira-Ida Skvortsova
Journal:  Mol Cancer       Date:  2019-03-30       Impact factor: 27.401

6.  Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment.

Authors:  Tessa Ya Sung Le Large; Btissame El Hassouni; Niccola Funel; Bart Kok; Sander R Piersma; Thang V Pham; Kenneth P Olive; Geert Kazemier; Hanneke W M van Laarhoven; Connie R Jimenez; Maarten F Bijlsma; Elisa Giovannetti
Journal:  Ther Adv Med Oncol       Date:  2019-05-10       Impact factor: 8.168

Review 7.  Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance.

Authors:  Patrick Santos; Fausto Almeida
Journal:  Cells       Date:  2020-06-11       Impact factor: 6.600

8.  Paclitaxel‑resistant gastric cancer MGC‑803 cells promote epithelial‑to‑mesenchymal transition and chemoresistance in paclitaxel‑sensitive cells via exosomal delivery of miR‑155‑5p.

Authors:  Mei Wang; Rong Qiu; Shaorong Yu; Xiaoyue Xu; Gang Li; Rongmin Gu; Caihong Tan; Wei Zhu; Bo Shen
Journal:  Int J Oncol       Date:  2018-10-22       Impact factor: 5.650

Review 9.  Exosomes and pancreatic diseases: status, challenges, and hopes.

Authors:  Xiao-Yu Guo; Fan Xiao; Jie Li; Yi-Nan Zhou; Wang-Jun Zhang; Bei Sun; Gang Wang
Journal:  Int J Biol Sci       Date:  2019-07-20       Impact factor: 6.580

10.  Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer.

Authors:  Xinyi Wang; Haiyang Zhang; Haiou Yang; Ming Bai; Tao Ning; Ting Deng; Rui Liu; Qian Fan; Kegan Zhu; Jialu Li; Yang Zhan; Guoguang Ying; Yi Ba
Journal:  Mol Oncol       Date:  2020-01-24       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.